| Today's Big NewsMar 7, 2023 |
|
Production of these particles, which can protect and deliver medicines and vaccines where they need to go in the body, is increasing. Learn more about how collaborating with a CDMO could be invaluable in developing nano-based systems. Learn more.
|
|
| By Annalee Armstrong A hero has arrived in Protagonist Therapeutics’ story, in the form of a Johnson & Johnson-partnered psoriasis med that has just cleared lesions in a mid-stage trial. |
|
|
|
By Max Bayer Volastra is doubling down on a top cancer target of interest while hedging its internal R&D bets, announcing it has scooped up a clinical-stage Amgen med at the same time as closing a $60 million funding round. |
By Nick Paul Taylor Immuneering is going all in on its universal-RAS candidate, leading it to suspend work on discovery-stage neuroscience programs and throw its resources behind an oncology program that is on course to deliver early clinical data in the coming months. |
Sponsored by Syneos Health This story centers on the benefits of implementing a full service commercial model to improve launch success for customers who lack the necessary infrastructure. Watch how Syneos Health expertise in Medical Affairs acted as a bridge to forge this full service commercial partnership, which helped meet critical deadlines for patients. |
|
Thursday, March 23, 2023 | 10am ET / 7am PT In this webinar, we will discuss customer-centric digital innovations that are improving overall process, product quality and performance, as well as transforming CDMO relationships. Register now to learn more!
|
|
By Nick Paul Taylor Flagship Pioneering is back with a new biotech designed to tackle a key drug development challenge: on-target, off-tissue toxicity. By creating drugs that only act at the diseased tissue, regardless of whether a target is expressed elsewhere, the biotech aims to provide powerful punches without the side effects. |
By James Waldron Some of Third Rock Ventures’ startups may have struggled in recent months, but the VC firm is nothing if not persistent. The latest biotech is Rapport Therapeutics, which is launching with $100 million in funding and a clinical-stage neuroscience asset born in Johnson & Johnson’s labs. |
By Gabrielle Masson Chiesi Farmaceutici is offering up to $637 million in biobucks to Affibody as part of a collaboration to develop new inhaled treatments for respiratory diseases. |
By Helen Floersh Computers that run off human brain cells sound like something out of a science fiction novel—but for scientists working in the newly dubbed field of organoid intelligence, bringing together neurons and silicon offers enormous potential for understanding and treating brain disease. |
By Kevin Dunleavy Days after Amarin shareholders sided with activist investor Sarissa Capital by removing Chairman Per Wold-Olsen and adding seven new board members, the troubled company has announced that seven of its holdover members have resigned. The resignations came a week after Alex Denner-led Sarissa boasted of a proxy win by a “huge landslide." |
By Andrea Park The FDA has yet to clear any PFA devices for use in the U.S., and Boston Scientific, Johnson & Johnson and Medtronic are among the medtech developers vying to snag the first nod—though the latter may have edged ahead with the publication of promising new study results this week. |
By Angus Liu Ongoing controversy around AbbVie’s patenting strategy for Humira didn’t stop CEO Rick Gonzalez from getting a pay bump in 2022. |
By Robert King President Joe Biden proposed to raise taxes on wealthy Americans and expand the drugs eligible for Medicare price negotiation to shore up the Medicare trust fund. |
Fierce podcastsDon't miss an episode |
| | This week on "The Top Line," we discuss 2022's M&A trends in the medtech sector and the surprising multibillion-dollar megadeals. We also cover the top headlines from this week. |
|
|---|
|
|
|
May 1-3, 2023 | Jersey City, NJ
Examine how the current changes to field medical will affect the role moving forward. Last chance to save on Early Bird Rates, Register Today!
|
|
| Executive SummaryRead about the latest survey results from over 200 biopharma executives and the changing approaches to building biologic drug development pipelines. Sponsored by: Twist Bioscience |
| WhitepaperHave you had your questions about mRNA/saRNA manufacturing unanswered during a webinar; have no fear, we have you covered here. Sponsored by: Aldevron |
| ResearchLike many top 10 and global pharma companies, an H1 client needed to diversify both its patient outreach and site investigator profiles for upcoming trials. Sponsored by: H1 |
| Whitepaper Discover the Power of Small with NanoplasmidTM – the next-generation plasmid for manufacturing today’s cell and gene therapies. Sponsored by: Aldevron |
| WhitepaperLearn more about critical success factors for your next launch based on the experience of 100+ pharma product launches. Sponsored by: Herspiegel Consulting |
| On-Demand Webinar See how high-throughput DNA synthesis combined with antibody engineering expertise provides end-to-end antibody discovery solutions. Sponsored by: Twist Bioscience |
| WhitepaperWhat are key considerations for intranasal delivery in the treatment of acute and chronic conditions? Sponsored By: Catalent |
| Research Learn more on Catalent’s step-wise approach for the definition and execution of Process Characterization for the production of a monoclonal antibody for late phase process characterization and development. Sponsored by: Catalent |
| WhitepaperExplore how clinical supply can be scaled up as decentralized programs progress, and how technological solutions can accelerate trial deployment. Sponsored by: Catalent Clinical Supply |
| Whitepaper As sponsors increasingly look to CROs to support their clinical studies, making and addressing certain clinical supply considerations at the outset of the relationship can reduce the risk of potentially unforeseen impact to budget and time later. Discover key issues sponsors should consider to help their CRO or partner of choice better understand their clinical supply needs. Sponsored by: Catalent |
| WhitepaperFor sponsors, cost is a key concern when it comes to managing the supply of their clinical trials. A financial project analyst (FPA) is a specialized expert who can help control clinical supply costs and keep the project within budget. Explore the critical role that a Financial Project Analyst plays in clinical trial supply and budget management. Sponsored by: Catalent |
| WhitepaperLearn how Catalent’s extensive network across APAC can meet a wide range of clinical supply needs for sponsors conducting trials within the region. Sponsored by: Catalent |
| WhitepaperDiscover key considerations that every trial sponsor should know when navigating the complex clinical supply distribution landscape across Asia-Pacific. Sponsored by: Catalent |
| WhitepaperHow can specialized expertise help you optimize your clinical supply chain? Learn about the roles and responsibilities of unique experts such as clinical supply management, project management, and financial project analysis. Sponsored by: Catalent Clinical Supply |
| Research Learn more on an approach for process characterization for the production of a monoclonal antibody, which will improve the efficiency and effectiveness of the process by targeting the right design and number of experiments. Sponsored by: Catalent |
| WhitepaperExplore Catalent’s newest clinical supply facility in Japan, including the comprehensive services & solutions it offers to help support trials both in-country & around the world. Sponsored by: Catalent |
| WhitepaperPlanning on using a CRO to support your next clinical study? This infographic outlines critical areas to address at the start of the relationship in order to ensure that budget and timelines keep on track for the duration of the trial. Sponsored by: Catalent |
| Case Study Learn more on an approach for process characterization for the production of a monoclonal antibody, which will improve the efficiency and effectiveness of the process by targeting the right design and number of experiments. Sponsored by: Catalent |
| |
|
